Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Comparison of Pain Relief After Arthroscopic Knee Surgery: Adductor Canal Block and Genicular Nerve Block

NCT06909851 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-03-10
Last updated
2025-04-04

Condition(s) studied

Opioid UsePain PostoperativeArthroscopic Knee Surgeries

Investigational drug(s) / intervention(s)

Adductor Canal Block (ACB)Genicular Nerve Block (GNB)

Adductor Canal Block (ACB): Evaluation of postoperative analgesic effectiveness of ACB block in participants undergoing arthroscopic knee surgery under spinal anesthesia.

Genicular Nerve Block (GNB): Evaluation of postoperative analgesic effectiveness of GNB block in participants undergoing arthroscopic knee surgery under spinal anesthesia.

Study summary

This prospective randomized study aims to compare the analgesic efficacy of Adductor Canal Block (ACB) and Genicular Nerve Block (GNB) groups to relieve postoperative pain in participants between ages of 18-72 undergoing arthroscopic knee surgery under spinal anesthesia. The main question it aims to answer is:

To demonstrate whether Adductor Canal Block or Genicular Nerve Block is more effective in postoperative analgesia in patients undergoing arthroscopic knee surgery based on pain scores, opioid consumption and patient satisfaction.

Arthroscopic knee surgeries cause severe pain especially with movement in the post-operative period. After surgery, the movements of the participants are severely restricted because of pain, which increases the possibility of complications and postpones post-operative knee exercises. In this study, the participants' pain status, VAS score, opioid consumption and patient satisfaction will be measured with a simple scoring system for 24 hours at predetermined time points and then compared. Both types of blocks have pain-relieving effects. This study will only investigate which one is more effective in reducing pain, and there will be no deficiency in relieving the pain of the participants.

Eligibility

Sex
ALL
Min age
18 Years
Max age
72 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Voluntary willingness to participate in the study. * Patients undergoing arthroscopic knee surgery (meniscus, ACL, arthroscopic intervention etc). * ASA I-II-III classification. * Aged between 18-72 years. * No contraindications for regional anesthesia, and deemed suitable for regional anesthesia by the anesthesiologist. * Undergoing surgery under spinal anesthesia. * Fully oriented and able to cooperate. Exclusion Criteria: * Undergoing surgery under general anesthesia. * Chronic analgesic use. * Presence of an active infection at the procedure site. * Outside the appropriate age range. * Inability to comply with postoperative pain/NRS follow-ups. * ASA IV-V classification. * Non-voluntary patients. * Pregnancy.

Primary outcome measure(s)

  • Effectiveness on Pain Scores (NRS) — Postoperative 24 hours
    Postoperative pain assessment is performed using the Numerical Rating Scale (NRS). Participants are asked about their rest pain at Baseline 0, postoperative 1st, 2nd, 4th, 6th, 12th, and 24th hours after applying a preoperative peripheral nerve block. With this method, participants rate their pain with a precise numerical value from 0 to 10. While zero(0) represents "no pain"; Ten (10) represents the opposite end of the pain continuum (e.g., "The most intense pain imaginable," "As intense pain as possible," "Maximum pain").

Trial sites (1)

FacilityCityRegionStatus
Başakşehir Çam & Sakura City Hospital Istanbul Turkey (Türkiye) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06909851 on ClinicalTrials.gov ↗ ← All trials in Turkey